前列腺床MRI引导自适应立体定向放疗的前瞻性安全性研究
该前瞻性队列纳入31例根治性前列腺切除术后生化复发患者,接受0.35T MR-LINAC的MR引导自适应SBRT(32.5 Gy分5次),部分患者加盆腔淋巴结照射或宏观病灶同步推量。中位随访8.8个月,无≥3级不良事件,6个月≥2级泌尿不良事件4.3%(1/23),患者报告生活质量维持。
要点
- MR引导自适应SBRT前列腺床治疗早期安全性良好,无≥3级不良事件。
- 6个月≥2级泌尿不良事件4.3%(1/23),以低级别尿失禁为主。
- EPIC-26泌尿域评分保持稳定,肠道域持续处于天花板水平。
核心结论
- 前列腺床MR引导自适应SBRT显示良好的早期安全性和耐受性,无≥3级不良事件,≥2级泌尿不良事件发生率低,且维持患者报告生活质量。
研究设计与样本
- 前瞻性队列研究,纳入31例根治性前列腺切除术后生化复发患者,接受0.35T MR-LINAC的MR引导自适应SBRT(32.5 Gy分5次)。
- 42%患者接受 elective 盆腔淋巴结照射(25 Gy分5次),9.7%接受宏观病灶同步推量(35 Gy分5次),77.4%接受同期雄激素剥夺治疗。
主要发现
- 中位随访8.8个月(IQR 6.1–16.8),任何时间点均未观察到≥3级不良事件。
- 治疗完成时急性≥2级泌尿不良事件3.3%(1/30),6个月时4.3%(1/23),以低级别尿失禁为主。
- 整个随访期间未观察到≥2级胃肠道不良事件。
- EPIC-26泌尿域评分基线79.6、6个月81.5,肠道域所有时间点中位100分。
- 中位PSA从治疗前0.31 ng/mL降至6个月0.02 ng/mL,12个月继续抑制于0.04 ng/mL(n=11),生化反应100%(31/31)。
临床怎么用
- 对于根治性前列腺切除术后生化复发患者,可考虑MR引导自适应SBRT作为前列腺床治疗后选,早期安全性良好。
- 治疗中需关注低级别尿失禁等泌尿不良事件,并利用EPIC-26和IPSS动态评估患者报告生活质量。
局限性
- 随访时间短(中位8.8个月),生化反应解释受限。
- 样本量小(31例),部分分析时点病例数更少(如12个月PSA仅n=11)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Magnetic resonance-guided radiotherapy (MRgRT) applied as stereotactic body radiotherapy to the prostate bed represents an emerging post-prostatectomy treatment approach, offering superior soft-tissue visualization and the potential for daily online adaptive planning. This study reports a prospective experience with MR-guided adaptive SBRT to the prostate bed, with a primary focus on treatment-related adverse events and patient-reported quality-of-life (QoL) outcomes. MATERIALS AND METHODS: A prospective cohort of 31 patients with biochemical recurrence following radical prostatectomy was treated with MR-guided adaptive SBRT (32.5 Gy in 5 fractions) using a 0.35 T MR-LINAC (MRIdian®, ViewRay). Elective pelvic nodal irradiation was delivered in 42% of patients (25 Gy in 5 fractions), and a simultaneous integrated boost (SIB) to macroscopic disease (35 Gy in 5 fractions) was administered in 9.7% of cases. Concomitant androgen deprivation therapy (ADT) was administered in 77.4% of patients. Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, and patient-reported outcomes were assessed using the Expanded Prostate Cancer Index Composite-26 (EPIC-26) and the International Prostate Symptom Score (IPSS). RESULTS: With a median follow-up of 8.8 months (IQR: 6.1-16.8), no grade ≥ 3 adverse events were observed at any time point. Acute grade ≥ 2 genitourinary (GU) adverse events were 3.3% at treatment completion (1/30) and 4.3% at 6 months (1/23), with low-grade urinary incontinence as the predominant event. "No grade ≥ 2 gastrointestinal (GI) adverse events were observed throughout the follow-up period.EPIC-26 urinary domain scores were preserved over time (baseline: 79.6; 6 months: 81.5), while bowel domain scores remained consistently at ceiling levels (median 100 points at all time points). Median prostate-specific antigen (PSA) declined from 0.31 ng/mL pre-treatment to 0.02 ng/mL at 6 months, with continued suppression at 12 months (0.04 ng/mL, n = 11). Biochemical response was 100% (31/31), although interpretation is limited by the short follow-up. CONCLUSIONS: MRgRT to the prostate bed demonstrates a favorable early safety and tolerability profile, with no grade ≥ 3 adverse events, low rates of grade ≥ 2 GU adverse events (4.3% at 6 months, 1/23), and absence of late grade ≥ 3 GI adverse events, while maintaining patient-reported QoL outcomes.
引用
- Pieretti DG, López-Campos F, Ocanto A, et al. MRI-guided adaptive stereotactic body radiotherapy for the prostate bed: a prospective study of safety, tolerability, and patient-reported quality-of-life outcomes. Clin Transl Radiat Oncol. 2026. PMID: 42571475. doi:10.1016/j.ctro.2026.101241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。